Simple Summary Stimulation of the host immune responses, through the use of biotech
drugs that remove a brake on the immune system (immune checkpoint inhibitors), is a …

Over the past few years, the NCCN Guidelines for Melanoma: Cutaneous have been
expanded to include pathways for treatment of microscopic satellitosis (added in v2. 2020) …

PURPOSE Combination of antiprogrammed cell death protein-1 (PD-1) plus anti–cytotoxic T-
cell lymphocyte-4 (anti-CTLA-4) immunotherapy shows greater response rates (RRs) than …

Colorectal cancer (CRC) is the second most common cause of cancer-related death in the
United States. Despite excellent prognosis for early stage disease, 5-year survival rates in …

The combination of ipilimumab and nivolumab is a highly active systemic therapy for
metastatic melanoma but can cause significant toxicity. We explore the safety and efficacy of …

Management of PD-1 blockade resistance in metastatic melanoma (MM) remains
challenging. Immunotherapy or chemotherapy alone provides limited benefit in this setting …

Immune checkpoint blockade (ICB) is an approved therapy for advanced metastatic
mismatch repair (MMR)‐deficient cancer regardless of tissue of origin. Although therapy is …

In recent years, several drugs have been approved for the treatment of patients with
metastatic cutaneous melanoma, completely reshaping the landscape of this aggressive …

Immune checkpoint inhibitors have shown great promise in treating patients with mismatch
repair deficient/microsatellite instability high (dMMR/MSI-H) colorectal cancer (CRC) …

Background More than half of melanoma patients taking first-line anti-PD-1 therapy either
express transient or no response at all. The efficacy and safety of secondary treatments for …